CNTX
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Context Therapeutics Inc. (CNTX) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F). The rating has held at C- for 9 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B+ (3.7) | C- (1.9) | D+ (1.6) | F (0.7) | C+ (2.6) | C- (2.1) |
| 2026-11-04 | B+ (3.7) | C- (1.9) | D+ (1.6) | F (0.5) | C+ (2.7) | C- (2.1) |
| 2026-10-28 | B+ (3.7) | D+ (1.8) | D+ (1.6) | F (0.6) | C+ (2.7) | C- (2.1) |
| 2026-10-21 | B+ (3.7) | D+ (1.8) | D+ (1.6) | F (0.6) | C+ (2.6) | C- (2.1) |
| 2026-10-14 | B+ (3.7) | D+ (1.8) | D+ (1.6) | F (0.7) | C+ (2.6) | C- (2.1) |